August 2026
1. CHEN R, Kim HJ, Bushra M, Phi Dang C, et al
   Childhood exposure to a sibling with Crohn's disease alters gut microbiome and Crohn's disease susceptibility.
   Gut. 2026 Aug 25:gutjnl-2026-339257. doi: 10.1136/gutjnl-2026-339257.
   

   >> Share

   
   
2. GHARAHDAGHI N, Yeh PJ, Vadakethala K, Coy M, et al
   Neutralising autoantibodies against IL-10 and HLA-DRB1*01:03 in paediatric patients with inflammatory bowel disease.
   Gut. 2026 Aug 11:gutjnl-2026-339329. doi: 10.1136/gutjnl-2026-339329.
   

   >> Share

   
   July 2026
3. WILS P, Nancey S, Messmer E, Bourreille A, et al
   Ustekinumab for fistulising perianal Crohn's disease: a randomised placebo-controlled trial from the GETAID.
   Gut. 2026 Jul 24:gutjnl-2026-339158. doi: 10.1136/gutjnl-2026-339158.
   

   >> Share

   
   
4. BOURGONJE AR, Innocenti G, Livanos AE, Prinzensteiner M, et al
   Deciphering the prodrome of inflammatory bowel disease up to 10 years before disease onset by massively parallel serology.
   Gut. 2026 Jul 23:gutjnl-2025-337762. doi: 10.1136/gutjnl-2025-337762.
   

   >> Share

   
   
5. YALCINKAYA A, Sandstrom E, Degrace EJ, Pigneur B, et al
   IL-10-neutralising autoantibodies in paediatric-onset inflammatory bowel disease.
   Gut. 2026 Jul 8:gutjnl-2026-338876. doi: 10.1136/gutjnl-2026-338876.
   

   >> Share

   
   
6. WANG D, Zhao X, Yang Q, Zhu D, et al
   SMOC2 mediates GLI1+ mesenchymal cell-driven fibrostenosis and predicts postoperative recurrence in Crohn's disease.
   Gut. 2026 Jul 8:gutjnl-2025-337952. doi: 10.1136/gutjnl-2025-337952.
   

   >> Share

   
   
7. COLWILL M, Honap S, Young AM, Magro F, et al
   Digital twins in IBD-bridging data, biology and trial innovation.
   Gut. 2026;75:1607-1619.
   

   >> Share

   
   May 2026
8. CHEN R, Turpin W, Allez M, Silverberg MS, et al
   From preclinical phase of Crohn's disease to postoperative recurrence: shared mechanisms and potential interventions.
   Gut. 2026 May 28:gutjnl-2025-337981. doi: 10.1136/gutjnl-2025-337981.
   

   >> Share

   
   April 2026
9. ZHANG J, Hu J, Tang X, Ruan Y, et al
   Quantifying artificial sweeteners and emulsifiers in Crohn's disease and its relationship with disease activity: the ENIGMA study - a novel and targeted approach.
   Gut. 2026 Apr 8:gutjnl-2024-333999. doi: 10.1136/gutjnl-2024-333999.
   

   >> Share

   
   
10. BIRDA CL, Jena A, Torres J, Ng SC, et al
    Road to IBD prevention in the Global South: a conceptual framework modelling from non-communicable diseases.
    Gut. 2026;75:1055-1066.
    

    >> Share

    
    March 2026
11. AWONIYI M, El Hag M, Hernandez J, Yang Q, et al
    Dysbiotic microbiota trigger colitis-associated colorectal cancer and imprint a distinctive bile acid profile in a PSC-IBD model.
    Gut. 2026 Mar 23:gutjnl-2025-336675. doi: 10.1136/gutjnl-2025-336675.
    

    >> Share

    
    
12. HENS B, D'Haens G, Ungaro RC, Colombel JF, et al
    Screening for preclinical Crohn's disease based on capsule endoscopy is not yet ready.
    Gut. 2026 Mar 2:gutjnl-2026-338303. doi: 10.1136/gutjnl-2026-338303.
    

    >> Share

    
    February 2026
13. 
    Correction: Patient-derived organoid biobank identifies epigenetic dysregulation of intestinal epithelial MHC-I as a novel mechanism in severe Crohn's Disease.
    Gut. 2026 Feb 18:gutjnl-2024-332043corr1. doi: 10.1136/gutjnl-2024-332043.
    

    >> Share

    
    
14. POWELL N
    Rise of prediagnostic molecular profiling in inflammatory bowel disease-can we close the door before the horse has bolted?
    Gut. 2026 Feb 13:gutjnl-2025-336049. doi: 10.1136/gutjnl-2025-336049.
    

    >> Share

    
    
15. DAI C, Huang YH, Jiang M
    Preclinical stages of Crohn's disease defined by faecal calprotectin in asymptomatic first-degree relatives.
    Gut. 2026 Feb 3:gutjnl-2026-338123. doi: 10.1136/gutjnl-2026-338123.
    

    >> Share

    
    
16. TURNER D, Kenigsberg S, Focht G, Croitoru K, et al
    Defining preclinical stages of Crohn's disease by faecal calprotectin and other risk factors: response to letter.
    Gut. 2026 Feb 3:gutjnl-2026-338188. doi: 10.1136/gutjnl-2026-338188.
    

    >> Share

    
    January 2026
17. IACUCCI M, Zammarchi I, Pugliano CL, Santacroce G, et al
    Shaping the future of postoperative recurrence in Crohn's disease: personalised approaches with AI-enabled imaging and multi-omics.
    Gut. 2026 Jan 27:gutjnl-2025-337171. doi: 10.1136/gutjnl-2025-337171.
    

    >> Share

    
    
18. PARIGI TL, Cominelli F
    Role of TL1A in perianal fistulising Crohn's disease: a new therapeutic target?
    Gut. 2026 Jan 23:gutjnl-2025-337684. doi: 10.1136/gutjnl-2025-337684.
    

    >> Share

    
    
19. CONSTANTINE-COOKE N, Gros B, Plevris N, Williams LJ, et al
    Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PRognostic effect of Environmental factors in Crohn's and Colitis (PREdiCCt) prospective cohort study.
    Gut. 2026 Jan 19:gutjnl-2025-337846. doi: 10.1136/gutjnl-2025-337846.
    

    >> Share

    
    
20. ZHANG J, Mak JWY, Ng SC
    Gut microbiome in IBD: past, present and the future.
    Gut. 2026;75:398-410.
    

    >> Share

    
    
21. MAYORGA L, Noguera Segura A, Campderros L, Pons-Tarin M, et al
    Distinct microbial mediators link diet to inflammation in Crohn's disease and ulcerative colitis.
    Gut. 2026 Jan 6:gutjnl-2025-337480. doi: 10.1136/gutjnl-2025-337480.
    

    >> Share

    
    December 2025
22. NOH Y, Choi A, Lee H, Yon DK, et al
    Proton pump inhibitors use and risk of inflammatory bowel disease in children.
    Gut. 2025 Dec 31:gutjnl-2025-337345. doi: 10.1136/gutjnl-2025-337345.
    

    >> Share

    
    
23. GUDINO V, Cho JW, Caballol B, Sanzo-Machuca A, et al
    TL1A-activated T cells remodel the rectal mucosa in patients with Crohn's disease with perianal fistulising disease.
    Gut. 2025 Dec 25:gutjnl-2025-336246. doi: 10.1136/gutjnl-2025-336246.
    

    >> Share

    
    
24. TAN H, Huang L, Wang J, Huang H, et al
    Parasutterella excrementihominis exacerbates experimental colitis and colitis-associated colorectal cancer via pathogenic NETosis activation.
    Gut. 2025 Dec 25:gutjnl-2025-335887. doi: 10.1136/gutjnl-2025-335887.
    

    >> Share

    
    
25. ZHOU L, Nie J, Feng Z, Li R, et al
    Fibroblast pentose phosphate pathway activation upon decreased circPLCE1 exacerbates intestinal fibrosis in Crohn's disease.
    Gut. 2025 Dec 13:gutjnl-2025-336415. doi: 10.1136/gutjnl-2025-336415.
    

    >> Share

    
    
26. TURNER D, Kenigsberg S, Focht G, Turpin W, et al
    Preclinical stages of Crohn's disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials.
    Gut. 2025 Dec 11:gutjnl-2025-336368. doi: 10.1136/gutjnl-2025-336368.
    

    >> Share

    
    
27. SCHREIBER S, Aden K, Tran F, Rosenstiel P, et al
    Rise of precision medicine: can it deliver on its promise in IBD?
    Gut. 2025;75:176-188.
    

    >> Share

    
    
28. MIYAUCHI E, Taida T, Uchiyama K, Nakanishi Y, et al
    Smoking affects gut immune system of patients with inflammatory bowel diseases by modulating metabolomic profiles and mucosal microbiota.
    Gut. 2025;75:46-56.
    

    >> Share

    
    
29. DE LUCA R, Arre V, Nardone S, Incerpi S, et al
    Gastrointestinal microbiota and inflammasomes interplay in health and disease: a gut feeling.
    Gut. 2025;75:161-175.
    

    >> Share

    
    October 2025
30. BRAGA-NETO MB, Qazi T, Fulmer C, Holubar SD, et al
    Cellular and molecular mechanisms in the pathogenesis of pouchitis: more than just the microbiota.
    Gut. 2025;74:1905-1915.
    

    >> Share

    
    September 2025
31. 
    Correction: British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025.
    Gut. 2025 Sep 26:gutjnl-2024-334395corr1. doi: 10.1136/gutjnl-2024-334395.
    

    >> Share

    
    
32. ASHTON JJ, Green Z, Beattie RM
    British Society of Gastroenterology adult guidelines on inflammatory bowel disease: what can we learn for children and young people?
    Gut. 2025 Sep 12:gutjnl-2025-336739. doi: 10.1136/gutjnl-2025-336739.
    

    >> Share

    
    
33. HAZIME H, Ducasa GM, Santander AM, Brito N, et al
    DUOX2 activation drives bacterial translocation and subclinical inflammation in IBD-associated dysbiosis.
    Gut. 2025;74:1589-1601.
    

    >> Share

    
    
34. GONZALEZ-ACERA M, Patankar JV, Erkert L, Cineus R, et al
    Integrated multimodel analysis of intestinal inflammation exposes key molecular features of preclinical and clinical IBD.
    Gut. 2025;74:1602-1615.
    

    >> Share

    
    August 2025
35. MAHADEVAN U, Seow CH, Barnes EL, Chaparro M, et al
    Global consensus statement on the management of pregnancy in inflammatory bowel disease.
    Gut. 2025 Aug 28:gutjnl-2025-336402. doi: 10.1136/gutjnl-2025-336402.
    

    >> Share

    
    July 2025
36. MO M, Sun J, Mikulic I, Ludvigsson JF, et al
    Inflammatory bowel disease linked to accelerated cognitive decline in individuals with dementia: a nationwide cohort study.
    Gut. 2025 Jul 11:gutjnl-2025-335370. doi: 10.1136/gutjnl-2025-335370.
    

    >> Share

    
    
37. 
    Correction: Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
    Gut. 2025;74:e16.
    

    >> Share

    
    
38. KOU F, Li XY, Feng Z, Hua J, et al
    GPR171 restrains intestinal inflammation by suppressing FABP5-mediated Th17 cell differentiation and lipid metabolism.
    Gut. 2025;74:1279-1292.
    

    >> Share

    
    
39. BOURGONJE AR, Andreu-Sanchez S, Gacesa R, Innocenti G, et al
    Crohn's disease and ulcerative colitis exhibit prediagnostic antibody signatures with shared and divergent changes towards disease onset.
    Gut. 2025 Jul 2:gutjnl-2024-334362. doi: 10.1136/gutjnl-2024-334362.
    

    >> Share

    
    June 2025
40. PAL P, Mateen MA, Pooja K, Marri UK, et al
    Small intestinal contrast ultrasound versus imaging and enteroscopy in Crohn's disease.
    Gut. 2025 Jun 27:gutjnl-2025-335697. doi: 10.1136/gutjnl-2025-335697.
    

    >> Share

    
    
41. MORAN GW, Gordon M, Sinopolou V, Radford SJ, et al
    British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025.
    Gut. 2025;74.
    

    >> Share

    
    
42. SUN Y, Huang X, Zhang Y, Bao W, et al
    Enterococcus faecalis hijacks FABP2 to activate quorum-sensing signals and aggravate Crohn's disease by inducing gut dysbiosis.
    Gut. 2025 Jun 8:gutjnl-2024-334604. doi: 10.1136/gutjnl-2024-334604.
    

    >> Share

    
    
43. BARNICH N, Arthur JC, Buisson A, Campbell BJ, et al
    Adherent-invasive Escherichia coli in Crohn's disease: the 25th anniversary.
    Gut. 2025 Jun 5:gutjnl-2025-335331. doi: 10.1136/gutjnl-2025-335331.
    

    >> Share

    
    May 2025
44. ALKHATEB O, Ftouni R, Abbas O, Mourad FH, et al
    Skin lesions and chest pain in a patient with Crohn's disease.
    Gut. 2025 May 24:gutjnl-2025-335547. doi: 10.1136/gutjnl-2025-335547.
    

    >> Share

    
    
45. BLACKWELL J, Plevris N, Bancil A, Kobayashi T, et al
    Withdrawal of antitumour necrosis factor in patients with inflammatory bowel disease in remission: a randomised placebo-controlled clinical trial of GETECCU.
    Gut. 2025 May 13:gutjnl-2025-334946. doi: 10.1136/gutjnl-2025-334946.
    

    >> Share

    
    
46. PAL P, Mateen MA, Sekaran A, Pooja K, et al
    Can transperineal ultrasound replace endoscopic ultrasound in staging distal ulcerative colitis?
    Gut. 2025 May 13:gutjnl-2025-335681. doi: 10.1136/gutjnl-2025-335681.
    

    >> Share

    
    April 2025
47. EAST JE, Gordon M, Nigam GB, Sinopoulou V, et al
    British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease.
    Gut. 2025 Apr 30:gutjnl-2025-335023. doi: 10.1136/gutjnl-2025-335023.
    

    >> Share

    
    
48. TSCHURTSCHENTHALER M
    Dietary modulation of the gut phageome: a cross-kingdom dialogue in Crohn's disease.
    Gut. 2025 Apr 29:gutjnl-2025-335261. doi: 10.1136/gutjnl-2025-335261.
    

    >> Share

    
    
49. WAN Z, Hao X, Huang F, Dai H, et al
    Unravelling the causality between inflammatory bowel disease and polycystic ovary syndrome mediated by gut microbiota and blood metabolism: insights from two prospective cohort studies.
    Gut. 2025 Apr 19:gutjnl-2024-334693. doi: 10.1136/gutjnl-2024-334693.
    

    >> Share

    
    March 2025
50. SU R, Wen W, Jin Y, Cao Z, et al
    Dietary whey protein protects against Crohn's disease by orchestrating cross-kingdom interaction between the gut phageome and bacteriome.
    Gut. 2025 Mar 23:gutjnl-2024-334516. doi: 10.1136/gutjnl-2024-334516.
    

    >> Share

    
    
51. BAMIAS G, Menghini P, Pizarro TT, Cominelli F, et al
    Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD.
    Gut. 2025;74:652-668.
    

    >> Share

    
    February 2025
52. GUISADO D, Talware S, Wang X, Davis A, et al
    Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn's disease.
    Gut. 2025 Feb 17:gutjnl-2024-333558. doi: 10.1136/gutjnl-2024-333558.
    

    >> Share

    
    
53. GUDINO V, Bartolome-Casado R, Salas A
    Single-cell omics in inflammatory bowel disease: recent insights and future clinical applications.
    Gut. 2025 Feb 4:gutjnl-2024-334165. doi: 10.1136/gutjnl-2024-334165.
    

    >> Share

    
    January 2025
54. AL BAKIR I, Curtius K, Cresswell GD, Grant HE, et al
    Low-coverage whole genome sequencing of low-grade dysplasia strongly predicts advanced neoplasia risk in ulcerative colitis.
    Gut. 2025 Jan 29:gutjnl-2024-333353. doi: 10.1136/gutjnl-2024-333353.
    

    >> Share

    
    
55. BONFILS L, Poulsen G, Agrawal M, Julsgaard M, et al
    Impact of prenatal and postnatal maternal IBD status on offspring's risk of IBD: a population-based cohort study.
    Gut. 2025;74:206-213.
    

    >> Share

    
    
56. TE GROEN M, Wijnands AM, den Broeder N, de Jong DJ, et al
    Surveillance in inflammatory bowel disease: white light endoscopy with segmental re-inspection versus dye-based chromoendoscopy - a multi-arm randomised controlled trial (HELIOS).
    Gut. 2025 Jan 16:gutjnl-2024-333446. doi: 10.1136/gutjnl-2024-333446.
    

    >> Share

    
    December 2024
57. ZHANG J
    Dysbiosis exists in unaffected relatives of inflammatory bowel disease (IBD): emphasising the critical phases in the developmental trajectory of gut microbiota.
    Gut. 2024 Dec 23:gutjnl-2024-333425. doi: 10.1136/gutjnl-2024-333425.
    

    >> Share

    
    
58. GISBERT JP, Donday MG, Riestra S, Lucendo AJ, et al
    Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
    Gut. 2024 Dec 20:gutjnl-2024-333385. doi: 10.1136/gutjnl-2024-333385.
    

    >> Share

    
    
59. ADLER J, Gadepalli S, Rahman M, Kim S, et al
    Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: post hoc analysis of the RISK study.
    Gut. 2024 Dec 12:gutjnl-2024-333280. doi: 10.1136/gutjnl-2024-333280.
    

    >> Share

    
    
60. NEURATH MF, Sands BE, Rieder F
    Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?
    Gut. 2024;74:9-14.
    

    >> Share

    
    November 2024
61. AMIOT A, Seksik P, Meyer A, Stefanescu C, et al
    Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial.
    Gut. 2024 Nov 25:gutjnl-2024-333281. doi: 10.1136/gutjnl-2024-333281.
    

    >> Share

    
    
62. WELLENS J, Sabino J, Vanuytsel T, Tack J, et al
    Recent advances in clinical practice: mastering the challenge-managing IBS symptoms in IBD.
    Gut. 2024 Nov 12:gutjnl-2024-333565. doi: 10.1136/gutjnl-2024-333565.
    

    >> Share

    
    October 2024
63. LV X, Zeng Y, Ma W, Zheng Y, et al
    Novel mouse model for studying transmural intestinal fibrosis and creeping fat formation in stricturing Crohn's disease.
    Gut. 2024 Oct 14:gutjnl-2024-333590. doi: 10.1136/gutjnl-2024-333590.
    

    >> Share

    
    
64. VICH VILA A, Zhang J, Liu M, Faber KN, et al
    Untargeted faecal metabolomics for the discovery of biomarkers and treatment targets for inflammatory bowel diseases.
    Gut. 2024;73:1909-1920.
    

    >> Share

    
    September 2024
65. ERKERT L, Gamez-Belmonte R, Kabisch M, Schodel L, et al
    Alzheimer's disease-related presenilins are key to intestinal epithelial cell function and gut immune homoeostasis.
    Gut. 2024;73:1618-1631.
    

    >> Share

    
    
66. CARPAY N, de Boer NKH, Neefjes-Borst A, Bots S, et al
    Severe multiple therapy refractory colitis in a 46-year-old man.
    Gut. 2024;73:1617-1736.
    

    >> Share

    
    August 2024
67. ESTEVINHO MM, Midya V, Cohen-Mekelburg S, Allin KH, et al
    Emerging role of environmental pollutants in inflammatory bowel disease risk, outcomes and underlying mechanisms.
    Gut. 2024 Aug 30:gutjnl-2024-332523. doi: 10.1136/gutjnl-2024-332523.
    

    >> Share

    
    
68. PIERRE N, Huynh-Thu VA, Baiwir D, Mazzucchelli G, et al
    External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab.
    Gut. 2024 Aug 12:gutjnl-2024-332648. doi: 10.1136/gutjnl-2024-332648.
    

    >> Share

    
    
69. JACOBS JP, Spencer EA, Helmus DS, Yang JC, et al
    Age-related patterns of microbial dysbiosis in multiplex inflammatory bowel disease families.
    Gut. 2024 Aug 9:gutjnl-2024-332475. doi: 10.1136/gutjnl-2024-332475.
    

    >> Share

    
    
70. ATREYA R
    Glowing insights: tracking vedolizumab in the mucosa of patients with IBD via molecular endoscopy.
    Gut. 2024;73:1406-1408.
    

    >> Share

    
    
71. VERSTOCKT B, Vancamelbeke M, Vermeire S
    Increased inflammatory state in IBD multiplex first-degree relatives not developing intestinal disease.
    Gut. 2024;73:1586-1588.
    

    >> Share

    
    
72. MAJUMDER S, Santacroce G, Maeda Y, Zammarchi I, et al
    Endocytoscopy with automated multispectral intestinal barrier pathology imaging for assessment of deep healing to predict outcomes in ulcerative colitis.
    Gut. 2024 Aug 6:gutjnl-2024-332894. doi: 10.1136/gutjnl-2024-332894.
    

    >> Share

    
    July 2024
73. DAI C, Huang YH
    Rare cause of liver lesion in a patient with ulcerative colitis.
    Gut. 2024 Jul 20:gutjnl-2024-333095. doi: 10.1136/gutjnl-2024-333095.
    

    >> Share

    
    
74. HOV JR
    Sclerosing cholangitis and inflammatory bowel disease: a paradoxical relationship?
    Gut. 2024 Jul 17:gutjnl-2024-332835. doi: 10.1136/gutjnl-2024-332835.
    

    >> Share

    
    
75. ADOLPH TE, Meyer M, Jukic A, Tilg H, et al
    Heavy arch: from inflammatory bowel diseases to metabolic disorders.
    Gut. 2024;73:1376-1387.
    

    >> Share

    
    June 2024
76. DENNISON TW, Edgar RD, Payne F, Nayak KM, et al
    Patient-derived organoid biobank identifies epigenetic dysregulation of intestinal epithelial MHC-I as a novel mechanism in severe Crohn's Disease.
    Gut. 2024 Jun 10:gutjnl-2024-332043. doi: 10.1136/gutjnl-2024-332043.
    

    >> Share

    
    
77. IACUCCI M, Santacroce G, Majumder S, Morael J, et al
    Opening the doors of precision medicine: novel tools to assess intestinal barrier in inflammatory bowel disease and colitis-associated neoplasia.
    Gut. 2024 Jun 8:gutjnl-2023-331579. doi: 10.1136/gutjnl-2023-331579.
    

    >> Share

    
    
78. LIN S, Wang J, Mukherjee PK, Mao R, et al
    Milk fat globule-epidermal growth factor 8 (MFGE8) prevents intestinal fibrosis.
    Gut. 2024;73:1110-1123.
    

    >> Share

    
    
79. BEDKE T, Stumme F, Tomczak M, Steglich B, et al
    Protective function of sclerosing cholangitis on IBD.
    Gut. 2024 Jun 5:gutjnl-2023-330856. doi: 10.1136/gutjnl-2023-330856.
    

    >> Share

    
    
80. HONAP S, Jairath V, Sands BE, Dulai PS, et al
    Acute severe ulcerative colitis trials: the past, the present and the future.
    Gut. 2024 Jun 4:gutjnl-2024-332489. doi: 10.1136/gutjnl-2024-332489.
    

    >> Share

    
    May 2024
81. MONAGHAN TM, Ugun-Klusek A, Finelli M, Gurnani P, et al
    Connecting inflammatory bowel and neurodegenerative diseases: microRNAs as a shared therapeutic intervention.
    Gut. 2024;73:1034-1036.
    

    >> Share

    
    April 2024
82. GABRIELS RY, van der Waaij AM, Linssen MD, Dobosz M, et al
    Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease.
    Gut. 2024 Apr 5:gutjnl-2023-331696. doi: 10.1136/gutjnl-2023-331696.
    

    >> Share

    
    
83. RIEDER F, Mukherjee PK, Massey WJ, Wang Y, et al
    Fibrosis in IBD: from pathogenesis to therapeutic targets.
    Gut. 2024;73:854-866.
    

    >> Share

    
    
84. KARMI N, Sun S, Festen EAM, Vich Vila A, et al
    Gut microbial metabolism of 5-aminosalicylic acid in inflammatory bowel disease.
    Gut. 2024 Apr 3:gutjnl-2024-332205. doi: 10.1136/gutjnl-2024-332205.
    

    >> Share

    
    March 2024
85. ANANTHAKRISHNAN AN
    Inflammatory bowel diseases: are we ready to recommend a preventive diet for infants?
    Gut. 2024;73:559-560.
    

    >> Share

    
    
86. SCHULZ-KUHNT A, Ruhle K, Javidmehr A, Dobronti M, et al
    ATP citrate lyase (ACLY)-dependent immunometabolism in mucosal T cells drives experimental colitis in vivo.
    Gut. 2024;73:601-612.
    

    >> Share

    
    February 2024
87. ABDELRAHIM M, Siggens K, Iwadate Y, Maeda N, et al
    New AI model for neoplasia detection and characterisation in inflammatory bowel disease.
    Gut. 2024 Feb 23:gutjnl-2023-330718. doi: 10.1136/gutjnl-2023-330718.
    

    >> Share

    
    
88. ZHANG L, Agrawal M, Ng SC, Jess T, et al
    Early-life exposures and the microbiome: implications for IBD prevention.
    Gut. 2024;73:541-549.
    

    >> Share

    
    
89. ADOLPH TE
    It is in the matrix: a molecular clue to fibro-stenotic Crohn's disease.
    Gut. 2024 Feb 20:gutjnl-2024-332016. doi: 10.1136/gutjnl-2024-332016.
    

    >> Share

    
    
90. AN H, Zhong M, Gan H
    Proton pump inhibitors and the risk of inflammatory bowel disease: a Mendelian randomisation study.
    Gut. 2024 Feb 15:gutjnl-2024-331904. doi: 10.1136/gutjnl-2024-331904.
    

    >> Share

    
    January 2024
91. GUO A, Ludvigsson J, Brantsaeter AL, Klingberg S, et al
    Early-life diet and risk of inflammatory bowel disease: a pooled study in two Scandinavian birth cohorts.
    Gut. 2024 Jan 30:gutjnl-2023-330971. doi: 10.1136/gutjnl-2023-330971.
    

    >> Share

    
    
92. SUN J, Yao J, Olen O, Halfvarson J, et al
    Familial coaggregation of inflammatory bowel disease with cardiovascular disease: a nationwide multigenerational cohort study.
    Gut. 2024 Jan 6:gutjnl-2023-331632. doi: 10.1136/gutjnl-2023-331632.
    

    >> Share

    
    
93. CHIRIAC MT, Hracsko Z, Gunther C, Gonzalez-Acera M, et al
    IL-20 controls resolution of experimental colitis by regulating epithelial IFN/STAT2 signalling.
    Gut. 2024;73:282-297.
    

    >> Share

    
    December 2023
94. ERIKSEN C, Danneskiold-Samsoe NB, Moll JM, Myers PN, et al
    Specific gut pathobionts escape antibody coating and are enriched during flares in patients with severe Crohn's disease.
    Gut. 2023 Dec 16:gutjnl-2023-330677. doi: 10.1136/gutjnl-2023-330677.
    

    >> Share

    
    
95. MINERVINA AA, Pogorelyy MV, Paysen S, Luening U, et al
    Crohn's-associated invariant T cells (CAITs) recognise small sulfonate molecules on CD1d.
    Gut. 2023;73:205-206.
    

    >> Share

    
    November 2023
96. TUN HM, Peng Y, Massimino L, Sin ZY, et al
    Gut virome in inflammatory bowel disease and beyond.
    Gut. 2023 Nov 10:gutjnl-2023-330001. doi: 10.1136/gutjnl-2023-330001.
    

    >> Share

    
    
97. ULLRICH KA, Derdau J, Baltes C, Battistella A, et al
    IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells.
    Gut. 2023;72:2081-2094.
    

    >> Share

    
    
98. NEURATH MF, Vieth M
    Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing.
    Gut. 2023;72:2164-2183.
    

    >> Share

    
    October 2023
99. MUKHOPADHYA I
    Is HBx protein the X factor in the pathogenesis of IBD?
    Gut. 2023;72:1808-1809.
    

    >> Share

    
    September 2023
100. MA Y, Zhang X, Xuan B, Li D, et al
     Disruption of CerS6-mediated sphingolipid metabolism by FTO deficiency aggravates ulcerative colitis.
     Gut. 2023 Sep 21:gutjnl-2023-330009. doi: 10.1136/gutjnl-2023-330009.
     

     >> Share

     
     
101. JIANG L, Li JC, Shen L, Tang BS, et al
     Association between inflammatory bowel disease and Alzheimer's disease: multivariable and bidirectional Mendelian randomisation analyses.
     Gut. 2023;72:1797-1799.
     

     >> Share

     
     
102. CHURCHHOUSE AM, Moffat VE, Selinger CP, Lamb CA, et al
     British Society of Gastroenterology interim framework for addressing the COVID-19-related backlog in inflammatory bowel disease colorectal cancer surveillance.
     Gut. 2023;72:1631-1634.
     

     >> Share

     
     August 2023
103. SCHWARZLER J, Zollner A, Dolejsi T, Mayr L, et al
     Inflammatory bowel disease in STAT1 gain-of-function immunodeficiency treated with precision medicine.
     Gut. 2023 Aug 24:gutjnl-2023-330588. doi: 10.1136/gutjnl-2023-330588.
     

     >> Share

     
     
104. CHETWOOD JD, Paramsothy S, Haifer C, Leong RW, et al
     Key metabolomic alterations are associated with ulcerative colitis disease state and activity: a validation analysis.
     Gut. 2023 Aug 17:gutjnl-2023-330196. doi: 10.1136/gutjnl-2023-330196.
     

     >> Share

     
     
105. WAUTERS L, Tito RY, Ceulemans M, Outtier A, et al
     Microbiome variance of the small bowel in Crohn's disease.
     Gut. 2023;72:1626-1628.
     

     >> Share

     
     July 2023
106. BECKER C, Adolph TE
     Disentangling tryptophan metabolism in inflammatory bowel diseases.
     Gut. 2023;72:1235-1236.
     

     >> Share

     
     
107. LEE JC
     Going deeper: molecular inflammatory scores in IBD.
     Gut. 2023;72:1233-1234.
     

     >> Share

     
     
108. MICHAUDEL C, Danne C, Agus A, Magniez A, et al
     Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases.
     Gut. 2023;72:1296-1307.
     

     >> Share

     
     
109. ARGMANN C, Hou R, Ungaro RC, Irizar H, et al
     Biopsy and blood-based molecular biomarker of inflammation in IBD.
     Gut. 2023;72:1271-1287.
     

     >> Share

     
     June 2023
110. DE BOER NKH, Simsek M, Meijer B, Neurath MF, et al
     Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease.
     Gut. 2023 Jun 28:gutjnl-2023-329679. doi: 10.1136/gutjnl-2023-329679.
     

     >> Share

     
     
111. LOPETUSO LR, Deleu S, Godny L, Petito V, et al
     The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease.
     Gut. 2023 Jun 20:gutjnl-2023-329948. doi: 10.1136/gutjnl-2023-329948.
     

     >> Share

     
     
112. SCHWARZFISCHER M, Niechcial A, Handler K, Morsy Y, et al
     TiO(2) nanoparticles abrogate the protective effect of the Crohn's disease-associated variation within the PTPN22 gene locus.
     Gut. 2023;72:1101-1114.
     

     >> Share

     
     
113. MILLET V, Gensollen T, Maltese M, Serrero M, et al
     Harnessing the Vnn1 pantetheinase pathway boosts short chain fatty acids production and mucosal protection in colitis.
     Gut. 2023;72:1115-1128.
     

     >> Share

     
     
114. DANNE C, Michaudel C, Skerniskyte J, Planchais J, et al
     CARD9 in neutrophils protects from colitis and controls mitochondrial metabolism and cell survival.
     Gut. 2023;72:1081-1092.
     

     >> Share

     
     May 2023
115. PAL P, Ramchandani M, Banerjee R, Viswakarma P, et al
     Technical performance and diagnostic yield of motorised spiral enteroscopy compared with single-balloon enteroscopy in suspected Crohn's disease: a randomised controlled, open-label study (the MOTOR-CD trial).
     Gut. 2023 May 17:gutjnl-2023-329885. doi: 10.1136/gutjnl-2023-329885.
     

     >> Share

     
     
116. LU H, Zhang C, Wu W, Chen H, et al
     MCPIP1 restrains mucosal inflammation by orchestrating the intestinal monocyte to macrophage maturation via an ATF3-AP1S2 axis.
     Gut. 2023;72:882-895.
     

     >> Share

     
     
117. ZUO L, Kuo WT, Cao F, Chanez-Paredes SD, et al
     Tacrolimus-binding protein FKBP8 directs myosin light chain kinase-dependent barrier regulation and is a potential therapeutic target in Crohn's disease.
     Gut. 2023;72:870-881.
     

     >> Share

     
     April 2023
118. GHATE A, Uhlig HH
     Defective microbial sensing and clearance in perianal Crohn's disease: a role for complement factor B.
     Gut. 2023 Apr 25:gutjnl-2023-329801. doi: 10.1136/gutjnl-2023-329801.
     

     >> Share

     
     
119. AKHLAGHPOUR M, Haritunians T, More SK, Thomas LS, et al
     Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis.
     Gut. 2023 Apr 20:gutjnl-2023-329689. doi: 10.1136/gutjnl-2023-329689.
     

     >> Share

     
     
120. ZHAO J, Chen J, Sun Y, Yuan S, et al
     Defining gene-lifestyle interactions in inflammatory bowel disease: progress towards understanding disease pathogenesis.
     Gut. 2023 Apr 4:gutjnl-2023-329875. doi: 10.1136/gutjnl-2023-329875.
     

     >> Share

     
     
121. YE BD
     Proton pump inhibitors and the risk of inflammatory bowel disease: cause, protopathic bias or others?
     Gut. 2023 Apr 4:gutjnl-2023-329506. doi: 10.1136/gutjnl-2023-329506.
     

     >> Share

     
     
122. HSU NY, Nayar S, Gettler K, Talware S, et al
     NOX1 is essential for TNFalpha-induced intestinal epithelial ROS secretion and inhibits M cell signatures.
     Gut. 2023;72:654-662.
     

     >> Share

     
     
123. AGRAWAL M, Poulsen G, Colombel JF, Allin KH, et al
     Maternal antibiotic exposure during pregnancy and risk of IBD in offspring: a population-based cohort study.
     Gut. 2023;72:804-805.
     

     >> Share

     
     March 2023
124. FAYE AS, Jess T
     Antibiotic use and inflammatory bowel disease: number needed to harm? Authors' reply.
     Gut. 2023 Mar 27:gutjnl-2023-329851. doi: 10.1136/gutjnl-2023-329851.
     

     >> Share

     
     
125. VICH VILA A, Hu S, Andreu-Sanchez S, Collij V, et al
     Faecal metabolome and its determinants in inflammatory bowel disease.
     Gut. 2023 Mar 23:gutjnl-2022-328048. doi: 10.1136/gutjnl-2022-328048.
     

     >> Share

     
     
126. LAUBE R, Selinger CP, Seow CH, Christensen B, et al
     Australian inflammatory bowel disease consensus statements for preconception, pregnancy and breast feeding.
     Gut. 2023 Mar 21:gutjnl-2022-329304. doi: 10.1136/gutjnl-2022-329304.
     

     >> Share

     
     
127. ZHANG E, Nguyen THO, Allen LF, Kedzierski L, et al
     Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments.
     Gut. 2023 Mar 6:gutjnl-2022-329136. doi: 10.1136/gutjnl-2022-329136.
     

     >> Share

     
     

Free Medical Abstracts
Privacy Policy
Sponsors
Share